Chemotherapy or Allogeneic Stem Cell Transplantation as Salvage Therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis.

ABSTRACT:

Introduction

The overall outcome of patients with refractory AML (rAML) remains poor. Though allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered as the only curative therapy, it is routinely recommended only for patients after remission with salvage chemotherapy.

Objective

In this study, we evaluated the impact of salvage chemotherapy or allo-HSCT on the overall outcome in rAML.

Methods

We collected the clinical data of 220 patients from 4 medical centers and performed retrospective analysis of prognosis factors, including salvage chemotherapy, intensity of chemotherapy, and allo-HSCT.

Results

A total of 29 patients received allo-HSCT directly without salvage chemotherapy, 26 patients achieved complete remission (CR) or complete remissi

SUBMITTER: Wang ZY 

PROVIDER: S-EPMC9393842 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature